Targeting IL-6 by genetic ablation or pharmacological inhibition in combination with CD40 stimulation or PD-1/PD-L1 signaling blockade improves T-cell infiltration into tumor and enhances mouse survival (56, 57). The gene discussed is PDCD1; the disease is neoplasm.